{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:14:52Z","timestamp":1788952492822,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:p>In a large population\u2010based cohort of patients with indolent B\u2010cell lymphoma, bendamustine\u2013rituximab was not associated with a statistically significant excess risk of secondary primary malignancies compared with cyclophosphamide\u2010based regimens after adjustment for confounders. These data contextualize prior safety concerns and support thoughtful optimization rather than abandonment of bendamustine\u2010based frontline therapies in indolent B\u2010cell lymphomas.<\/jats:p>","DOI":"10.1002\/cncr.70527","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:32:54Z","timestamp":1783420374000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bendamustine in indolent lymphoma: Letting the dust settle\u00a0down"],"prefix":"10.1002","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2582-3500","authenticated-orcid":false,"given":"Jacopo","family":"Olivieri","sequence":"first","affiliation":[{"name":"Clinica Ematologica Centro Trapianti e Terapie Cellulari \u201cCarlo Melzi\u201d Azienda Sanitaria Universitaria Friuli Centrale  Udine Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valter","family":"Gattei","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Onco\u2010Hematology Unit Centro di Riferimento Oncologico di Aviano IRCCS  Aviano, Pordenone Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6163-200X","authenticated-orcid":false,"given":"Luigino","family":"Dal Maso","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit Centro di Riferimento Oncologico di Aviano IRCCS  Aviano, Pordenone Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2026.102990"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(24)00141\u20104"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70327"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.842986"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(12)61763\u20102"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102013\u201011\u2010531327"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000258"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.8960"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102307"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02370"},{"key":"e_1_2_5_13_1","unstructured":"Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden follicular lymphoma (FIL_FOLL19). ClinicalTrials.gov identifier: NCT05058404. Accessed July 3 2026.https:\/\/clinicaltrials.gov\/study\/NCT05058404"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102021\u2010148581"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000723"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025018546"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20105357"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2025.09.009"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70527","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:39:07Z","timestamp":1788950347000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":17,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,15]]}},"alternative-id":["10.1002\/cncr.70527"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70527","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2026-07-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70527"}}